Skip to main content

ADVERTISEMENT

risk sharing

Research in Review
06/12/2017
JCP Editors
A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified, published in PLOS One (June 7, 2017;12[6]:e0179216). ----- Related Content Modified...
A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified, published in PLOS One (June 7, 2017;12[6]:e0179216). ----- Related Content Modified...
A...
06/12/2017
Journal of Clinical Pathways
Research in Review
05/12/2017
JCP Editors
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early...
05/12/2017
Journal of Clinical Pathways
Research in Review
05/09/2017
JCP Editors
Patients with colorectal cancer can decrease their risk of disease-related mortality by 54% if they consume certain types of food, according to a study presented at Digestive Disease Week (May 6-9, 2017; Chicago, IL;...
Patients with colorectal cancer can decrease their risk of disease-related mortality by 54% if they consume certain types of food, according to a study presented at Digestive Disease Week (May 6-9, 2017; Chicago, IL;...
...
05/09/2017
Journal of Clinical Pathways
Research in Review
05/01/2017
JCP Editors
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early...
05/01/2017
Journal of Clinical Pathways
Research in Review
04/28/2017
JCP Editors
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...
...
04/28/2017
Journal of Clinical Pathways
Research in Review
04/27/2017
JCP Editors
A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...
A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...
A...
04/27/2017
Journal of Clinical Pathways
Department
04/12/2017
JCP Editors
Results of a recent survey of the cancer care experience revealed barriers to navigating cancer care, including high costs and lack of information about how treatment decisions are made. ----- Related...
Results of a recent survey of the cancer care experience revealed barriers to navigating cancer care, including high costs and lack of information about how treatment decisions are made. ----- Related...
...
04/12/2017
Journal of Clinical Pathways
Research in Review
03/06/2017
JCP Editors
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of...
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of...
An...
03/06/2017
Journal of Clinical Pathways
Research in Review
02/01/2017
JCP Editors
Treating advanced prostate cancer with androgen deprivation therapy (ADT) does not increase risk of Alzheimer’s disease, according to research published in the Journal of Clinical Oncology. ADT is prescribed to men...
Treating advanced prostate cancer with androgen deprivation therapy (ADT) does not increase risk of Alzheimer’s disease, according to research published in the Journal of Clinical Oncology. ADT is prescribed to men...
...
02/01/2017
Journal of Clinical Pathways
Research in Review
01/11/2017
JCP Editors
Men diagnosed with prostate cancer may become distressed and consequently choose unnecessarily aggressive treatment options, according to a new study published in the Journal of Oncology. Prostate cancer is a highly...
Men diagnosed with prostate cancer may become distressed and consequently choose unnecessarily aggressive treatment options, according to a new study published in the Journal of Oncology. Prostate cancer is a highly...
Men...
01/11/2017
Journal of Clinical Pathways